Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12579013 | 0.78 | HSD17B10 (0.45) | KDM4EHSD17B10 | |
| SCHEMBL803483 | 0.72 | KDM4E (0.40) | KDM4EHSD17B10 | |
| SCHEMBL9004152 | 0.69 | HDAC8 (0.31) | — | |
| SCHEMBL25530016 | 0.68 | HSD17B10 (0.34) | KDM4EHSD17B10 | |
| SCHEMBL26860466 | 0.68 | HSD17B10 (0.34) | KDM4EHSD17B10 | |
| SCHEMBL2625506 | 0.68 | ALDH1A1 (0.38) | KDM4EHSD17B10 | |
| SCHEMBL2718887 | 0.68 | HSD17B10 (0.42) | KDM4EHSD17B10 | |
| SCHEMBL2719104 | 0.68 | HSD17B10 (0.34) | KDM4EHSD17B10 | |
| SCHEMBL18075581 | 0.68 | PDE2A (1.00) | PDE2AKDM4E | |
| SCHEMBL17322821 | 0.66 | PDE2A (0.48) | PDE2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | PDE2A 3549/4885KDM4E 2472/4885HSD17B10 2993/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | PDE2A 836/4885KDM4E 3792/4885HSD17B10 223/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | PDE2A 1379/4885KDM4E 1281/4885HSD17B10 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.